ArticleMedical oncology (Northwood, London, England)2015
Serine protease HtrA1 as an inhibitor on proliferation invasion and migration of gastric cancer.
Article in Medical oncology (Northwood, London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- HtrA1 as a promising tissue marker in cancer: a meta-analysis.BMC cancer · 2018Pooled it
- Host andGut microbes · 2026Article
- High temperature requirement A1 in cancer: biomarker and therapeutic target.Cancer cell international · 2021Review
- High SPINK4 Expression Predicts Poor Outcomes among Rectal Cancer Patients Receiving CCRT.Current oncology (Toronto, Ont.) · 2021Article
- Novel therapeutic compounds for prostate adenocarcinoma treatment: An analysis using bioinformatic approaches and the CMap database.Medicine · 2020Article
- HtrA1 suppresses the growth of pancreatic cancer cells by modulating Notch-1 expression.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HtrA1, as serine protease lower expressed in various human solid tumors, can down-regulate cell growth and proliferation. In this study, we focus on whether overexpressed HtrA1 can inhibit the growth of gastric cancer in vitro. This study found the HtrA1 is lower expressed in gastric cancer tissue than in normal gastric tissue. When HtrA1 is highly expressing with recombinant plasmid in gastric cancer cell lines SGC-7901 and AGS, it weakened cell proliferation, invasion, and migration in vitro. These data suggested that HtrA1 as an inhibitor in gastric cancer cells resulted in anti-proliferation, reduced invasion, decreased migration, and suppressed growth and may be an effective molecular targets on gastric cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.